180 Life Sciences Sets Virtual Annual Meeting for July 24
Ticker: FRMM · Form: DEF 14A · Filed: Jul 7, 2025 · CIK: 1690080
| Field | Detail |
|---|---|
| Company | 180 Life Sciences CORP. (FRMM) |
| Form Type | DEF 14A |
| Filed Date | Jul 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Corporate Governance, Virtual Meeting, Pharmaceuticals, SEC Filing, Shareholder Vote
Related Tickers: FRMM
TL;DR
**FRMM's virtual annual meeting on July 24th is a procedural formality, but investors should still log in to vote on governance issues.**
AI Summary
180 Life Sciences Corp. (FRMM) filed a Definitive Proxy Statement (DEF 14A) on July 7, 2025, for its annual meeting scheduled for July 24, 2025, at 9:00 a.m. Pacific Time. The meeting will be held virtually via an audio teleconference at https://agm.issuerdirect.com/ATNF-2025. Stockholders can attend, vote, and submit questions online using their Control ID and Request ID. The filing indicates that no filing fee was required for this definitive proxy statement. The company, headquartered in Palo Alto, California, with a business phone of 650-507-0669, is classified under Pharmaceutical Preparations (SIC 2834). This DEF 14A primarily outlines the procedural aspects of the upcoming annual meeting, including how stockholders can participate and access the Annual Report on Form 10-K for the year ended December 31, 2024, available at https://www.iproxydirect.com/ATNF. Specific financial figures for revenue or net income are not detailed within this procedural filing, focusing instead on corporate governance and meeting logistics.
Why It Matters
This DEF 14A filing is crucial for 180 Life Sciences Corp. investors as it details the logistics for the 2025 annual meeting, where key corporate governance decisions, such as director elections and executive compensation, are typically addressed. The virtual format, accessible via https://agm.issuerdirect.com/ATNF-2025, ensures all stockholders can participate regardless of location, promoting transparency and engagement. For employees and customers, the outcomes of this meeting could influence strategic direction and leadership stability. In the competitive pharmaceutical preparations sector, effective governance is vital for maintaining investor confidence and driving long-term value.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A filing is a standard procedural document for an annual meeting, primarily detailing logistics like the date, time, and virtual access for the July 24, 2025 meeting. It does not contain new financial disclosures, strategic shifts, or adverse events that would immediately impact the company's operations or valuation. The filing explicitly states 'No fee required,' indicating a routine submission.
Analyst Insight
Investors should review the full proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2024, available at https://www.iproxydirect.com/ATNF, to understand the proposals to be voted on. Participate in the virtual annual meeting on July 24, 2025, at 9:00 a.m. Pacific Time to exercise voting rights and engage with management.
Key Numbers
- 2025-07-07 — Filing Date (Date the DEF 14A was filed with the SEC)
- 2025-07-24 — Annual Meeting Date (Date of 180 Life Sciences Corp.'s 2025 annual meeting)
- 9:00 a.m. — Annual Meeting Time (Pacific Time start of the virtual annual meeting)
- 001-38105 — SEC File Number (SEC file number for 180 Life Sciences Corp.)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant as Specified in Charter
- Board of Directors (person) — governing body of 180 Life Sciences Corp.
- July 24, 2025 (date) — date of the 2025 annual meeting
- 9:00 a.m. Pacific Time (time) — start time of the 2025 annual meeting
- https://agm.issuerdirect.com/ATNF-2025 (website) — virtual meeting site for the annual meeting
- Palo Alto, California (location) — business address of 180 Life Sciences Corp.
- 650-507-0669 (phone_number) — business phone of 180 Life Sciences Corp.
- December 31, 2024 (date) — fiscal year end for the Annual Report on Form 10-K
- SEC (regulator) — Securities and Exchange Commission
- KBL Merger Corp. IV (company) — former name of 180 Life Sciences Corp.
FAQ
When is 180 Life Sciences Corp.'s 2025 annual meeting?
180 Life Sciences Corp.'s 2025 annual meeting is scheduled for Thursday, July 24, 2025, at 9:00 a.m. Pacific Time, as stated in the DEF 14A filing.
How can stockholders attend the 180 Life Sciences Corp. annual meeting?
Stockholders can attend the 180 Life Sciences Corp. annual meeting virtually via an audio teleconference by logging in at https://agm.issuerdirect.com/ATNF-2025 using their Control ID and Request ID.
What is the purpose of a DEF 14A filing for 180 Life Sciences Corp.?
A DEF 14A filing, like the one from 180 Life Sciences Corp., is a definitive proxy statement used to inform stockholders about an upcoming annual meeting, detailing proposals to be voted on, director nominations, and other corporate governance matters.
Where can I find 180 Life Sciences Corp.'s Annual Report on Form 10-K?
The Annual Report on Form 10-K for 180 Life Sciences Corp. for the year ended December 31, 2024, is available at https://www.iproxydirect.com/ATNF, as indicated in the DEF 14A filing.
What is 180 Life Sciences Corp.'s business address?
180 Life Sciences Corp.'s business address is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, according to the DEF 14A filing.
What is the SIC code for 180 Life Sciences Corp.?
180 Life Sciences Corp. is classified under Standard Industrial Classification (SIC) code 2834, which corresponds to Pharmaceutical Preparations.
Will 180 Life Sciences Corp.'s annual meeting be held in person?
No, the DEF 14A explicitly states that stockholders will not be able to attend the annual meeting physically; it will be held via an audio teleconference.
How can 180 Life Sciences Corp. stockholders vote during the virtual annual meeting?
Stockholders of 180 Life Sciences Corp. can vote their shares electronically during the virtual annual meeting using their Request ID, in addition to submitting a proxy prior to the meeting.
What was 180 Life Sciences Corp.'s former company name?
The former company name for 180 Life Sciences Corp. was KBL Merger Corp. IV, with the name change occurring on November 15, 2016.
What is the significance of the 'No fee required' checkbox in the DEF 14A filing?
The 'No fee required' checkbox in the DEF 14A filing signifies that this is a routine definitive proxy statement, and the associated filing fees were either paid with preliminary materials or are not applicable under SEC rules 14a-6(i)(1) and 0-11.
Industry Context
180 Life Sciences Corp. operates within the Pharmaceutical Preparations sector (SIC 2834). This industry is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Companies in this space focus on developing novel therapeutics to address unmet medical needs.
Regulatory Implications
As a pharmaceutical company, 180 Life Sciences Corp. is subject to extensive regulatory scrutiny regarding drug development, clinical trials, manufacturing, and marketing. Compliance with FDA regulations and other health authorities is critical. Any failure to adhere to these regulations can result in significant penalties, delays in product approval, or reputational damage.
What Investors Should Do
- Review the DEF 14A and accompanying Annual Report on Form 10-K.
- Attend the virtual annual meeting on July 24, 2025, at 9:00 a.m. Pacific Time.
- Prepare Control ID and Request ID for virtual meeting access.
Key Dates
- 2025-07-07: Filing of Definitive Proxy Statement (DEF 14A) — Provides formal notification to shareholders about the upcoming annual meeting and related proposals.
- 2025-07-24: Annual Meeting of Stockholders — Key date for shareholder voting on corporate matters and electing directors.
- 2024-12-31: Fiscal Year End — Marks the end of the reporting period for the company's audited financial statements included in the Annual Report.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC that provides shareholders with information about matters to be voted on at an annual or special meeting. (This is the primary document filed by 180 Life Sciences Corp. for its upcoming annual meeting.)
- Annual Meeting
- The yearly gathering of a company's shareholders to discuss corporate affairs, vote on proposals, and elect directors. (The central event discussed in the DEF 14A, detailing how shareholders can participate.)
- Control ID and Request ID
- Unique identifiers provided to shareholders to allow them to access the virtual meeting, vote, and submit questions. (Essential credentials for shareholders to participate in the virtual annual meeting.)
- Annual Report on Form 10-K
- A comprehensive report filed annually by public companies with the SEC, containing detailed financial information and business operations. (Provides the audited financial statements for the year ended December 31, 2024, which shareholders can access alongside the proxy statement.)
- SIC Code
- Standard Industrial Classification code used to categorize businesses by industry. 2834 represents Pharmaceutical Preparations. (Classifies 180 Life Sciences Corp. within the pharmaceutical sector.)
Year-Over-Year Comparison
This filing is a routine DEF 14A for the 2025 annual meeting. As it is a procedural document focused on meeting logistics and governance, it does not contain comparative financial data such as revenue or net income figures against the prior year's filing. Specific financial performance details would typically be found in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is referenced but not detailed within this proxy statement.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 7, 2025 by Board of Directors regarding 180 Life Sciences Corp. (FRMM).